...
首页> 外文期刊>Physics in medicine and biology. >Investigating multi-leaf collimator tracking in stereotactic arrhythmic radioablation (STAR) treatments for atrial fibrillation
【24h】

Investigating multi-leaf collimator tracking in stereotactic arrhythmic radioablation (STAR) treatments for atrial fibrillation

机译:调查立体定向心律失常放射性(星)治疗的多叶准直器跟踪进行心房颤动

获取原文
获取原文并翻译 | 示例

摘要

Stereotactic arrhythmia radioablation (STAR) is an emerging treatment option for atrial fibrillation (AF). However, it faces possibly the most challenging motion compensation scenario: both respiratory and cardiac motion. Multi-leaf collimator (MLC) tracking is clinically used for lung cancer treatments but its capabilities with intracardiac targets is unknown. We report the first experimental results of MLC tracking for intracardiac targets. Five AF STAR plans of varying complexity were created. All delivered 5 x 10 Gy to both pulmonary vein antra. Three healthy human target motion trajectories were acquired with ultrasound and programmed into a motion platform. Plans were delivered with a linac to a dosimeter placed on the motion platform. For each motion trace, each plan was delivered with no MLC tracking and with MLC tracking with and without motion prediction. Dosimetric accuracy was assessed with gamma-tests and dose metrics. MLC tracking improved the dosimetric accuracy in all measurements compared to non-tracking experiments. The average 2%/ 2 mm gamma-failure rate was improved from 13.1% with no MLC tracking to 5.9% with MLC tracking (p 0.001) and 7.2% with MLC tracking and no motion prediction (p 0.001). MLC tracking significantly improved the consistency between planned and delivered target dose coverage. The 95% target coverage with the prescription dose (V100) was improved from 60% of deliveries with no MLC tracking to 80% of deliveries with MLC tracking (p = 0.03). MLC tracking was successfully implemented for the first time for intracardiac motion compensation. MLC tracking provided significant dosimetric accuracy improvements in AF STAR experiments, even with challenging cardiac and respiratory-induced target motion and complex treatment plans. These results warrant further investigation and optimisation of MLC tracking for intracardiac target motion compensation.
机译:立体定向心律失常可线性(星)是心房颤动(AF)的新出现的治疗选择。然而,它可能面临最具挑战性的运动补偿情景:呼吸和心动。多叶准直器(MLC)跟踪临床上用于肺癌治疗,但其与心内靶点的能力是未知的。我们报告了肠内靶标的MLC跟踪的第一个实验结果。建立了五个不同复杂性的AF星星计划。所有肺静脉ANTRA都送了5 x 10 gy。使用超声波获得三个健康的人类目标运动轨迹,并编程到运动平台中。计划用LinaC向放置在运动平台上的剂量计。对于每个运动迹线,每个平面都没有使用MLC跟踪和MLC跟踪,并且没有运动预测。用γ试验和剂量指标评估剂量测量精度。与非跟踪实验相比,MLC跟踪改善了所有测量中的剂量精度。平均2%/ 2mmγ破坏率从13.1%提高,没有MLC跟踪的5.9%,MLC跟踪(P <0.001)和MLC跟踪和7.2%,没有运动预测(P <0.001)。 MLC跟踪显着提高了计划和递送的目标剂量覆盖率之间的一致性。 95%的目标覆盖与处方剂量(V100)的覆盖率从60%的交付量改善,没有MLC跟踪到80%的MLC跟踪的交付(P = 0.03)。 MLC跟踪是第一次成功实施的,以进行心内运动补偿。 MLC跟踪在AF STAR实验中提供了显着的描述,即使具有挑战性的心脏和呼吸诱导的目标运动和复杂的治疗计划。这些结果需要进一步调查和优化心内靶运动补偿的MLC跟踪。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号